Jade Biosciences, Inc.
JBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.5B
Close$
$2.80
88.3% downside
Current Fair Value
88.3% downsideOvervalued by 88.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.50 Billion |
|---|---|
| Enterprise Value | $1.40 Billion |
| Dividend Yield | $2.40 (-) |
| Earnings per Share | $-4.06 |
| Beta | 1.49 |
| Outstanding Shares | 61,050,775 |
Return
| Return on Equity | -42.94% |
|---|---|
| Return on Assets | -40.01% |
| Return on Invested Capital | -42.44% |
Valuation & Multiples
| P/E Ratio | -9.69 |
|---|---|
| PEG | -13.18 |
| Price to Sales | - |
| Price to Book Ratio | 3.4 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.47 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.73
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 624.41% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 88▼ 99.87% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 15.45%▼ 70.83% |
|---|---|
| Total Invested | $198.06M▼ 71.72% |
| Investors Holding | 42▼ 81.00% |
ESG Score
No data
About Jade Biosciences, Inc.
50 employees
CEO: Tom Frohlich Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) ...